Opinion|Videos|December 18, 2024
Iron Deficiency and Cardiovascular Interventions
Author(s)Orly Vardeny, PharmD, MS
A panelist discusses how the multicenter ferric carboxymaltose trial employed a prospective design to evaluate iron supplementation's impact on heart failure outcomes, strategically selecting hospitalization reduction as the primary end point due to its clinical relevance and statistical power considerations.
Advertisement
Video content above is prompted by the following:
- For the ferric carboxymaltose study “Assessing the Effectiveness of Ferric Carboxymaltose for Treating Iron Deficiency in Heart Failure Patients Along With its Effect on Clinical Parameters,” could you explain the study's prospective, multicenter design, including how patients were allocated and the rationale behind the primary end point?
- What were the most notable clinical outcomes observed in this trial?
- Can you explain why there was a reduction in hospitalizations but no impact on mortality?
- What are the potential clinical implications of intravenous iron supplementation in patients with heart failure?
- What emerging research directions and knowledge gaps are highlighted by these cardiovascular clinical investigations, and how might future studies build upon these foundational findings?
Advertisement
Related to this article
Although PMOS Awareness Month has ended, the conversation continues, with experts saying closing diagnostic and care gaps requires ongoing efforts.
Invivyd's VYD2311 shows superior safety and tolerability vs Comirnaty in the phase 3 LIBERTY trial, with no vaccine interference.
Survodutide achieved up to 13.1% weight loss vs 3.1% with placebo at 76 weeks in adults with obesity and T2D in the phase 3 SYNCHRONIZE-2 trial.
A rare case of soft-tissue sarcoma spreading to the heart shows how multimodal imaging guided diagnosis and care in a 36-year-old man.
Weekend catch-up sleep was associated with lower odds of overactive bladder and milder symptoms, with the benefit concentrated in the first 1.5 hours.
The triple agonist also lowered HbA1C by up to 1.6% over 80 weeks, with up to 40% of participants reaching normal levels.
A network meta-analysis found vibegron outperformed mirabegron and tolterodine on several OAB efficacy measures but had higher odds of adverse events.
A US modeling study found tirzepatide and semaglutide cost-effective for MASH, while resmetirom exceeded the $100,000/QALY threshold.
Advertisement
Advertisement
Trending on AJMC
1
Dual Agonist Survodutide Delivers Up to 13.1% Weight Loss in T2D
2
CMS Finalizes Mandatory GLOBE Model to Test Lower Part B Drug Costs
3
FDA Expands Mavacamten Label to Include Children With oHCM
4
Specialty Pharmacy Faces Gaps in Payment, Data, and Patient Trust
5